RxDoctor Payments Data

Alicia Almendral, MD

Family Medicine · Bronx, NYNPI 1932125465

Payments from drug & device makers

$2,208in general payments, 2019–2025

Across 38 payments — averaging $58.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$1K
  • Acelrx Pharmaceuticals, Inc.$286
  • Novo Nordisk$182
  • Baxter Healthcare$101
  • Boehringer Ingelheim$64
  • Lilly USA, LLC$49
  • plus $69 from 2 others

What the payments were for

  • Travel & lodging$34216%
  • Food & beverage$1,86584%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,208 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$26,524
Medicare patients
28
Services billed
499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate23$28,038
FarxigaDapagliflozin Propanediol11$16,543
JardianceEmpagliflozin13$10,390
Losartan Potassium139$2,070
Diclofenac Sodium13$1,607
Albuterol Sulfate HfaAlbuterol Sulfate32$1,077
Atorvastatin Calcium132$890
Simvastatin72$808
Amlodipine Besylate104$757
Metformin Hcl120$755
Alendronate Sodium94$711
Metoprolol Succinate32$691
Levothyroxine Sodium38$566
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide18$463
Nifedipine ErNifedipine14$423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$64$10,39013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →